Insider Transactions
| Date | Name | Title | Type | Filing | Shares Traded | Price Range | Total Held |
|---|---|---|---|---|---|---|---|
| Feb 01, 2008 | Director, Ten Percent Owner | Open market or private purchase of non-derivative or derivative security | Form 4 | 2,200 | $9.35 | 323,315 | |
| Jul 25, 2008 | Director | Open market or private sale of non-derivative or derivative security | Form 4 | 2,217 | $15.43 | 1,923,005 | |
| May 24, 2011 | VP, Pharmacology & Biology | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | Form 4 | 2,250 | $0.64 | 3,958 | |
| May 24, 2011 | VP, Pharmacology & Biology | Open market or private sale of non-derivative or derivative security | Form 4 | 2,250 | $7.50 | 1,708 | |
| May 24, 2011 | VP, Pharmacology & Biology | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | Form 4 | 2,250 | -- | 543 | |
| Jun 27, 2007 | Ten Percent Owner | Open market or private purchase of non-derivative or derivative security | Form 4/A | 2,291 | $11.30 | 75,702 | |
| Jun 27, 2007 | Director, Ten Percent Owner | Open market or private purchase of non-derivative or derivative security | Form 4 | 2,291 | $11.30 | 75,702 | |
| Sep 29, 2008 | Senior VP, Drug Development | Open market or private sale of non-derivative or derivative security | Form 4 | 2,300 | $15.03 | 51,816 | |
| Jun 08, 2015 | SVP, Program Management | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | Form 4 | 2,314 | -- | 21,506 | |
| Nov 21, 2008 | Director | Open market or private sale of non-derivative or derivative security | Form 4 | 2,348 | $8.50 | 1,667,313 |
* Represents the number of non-derivative securities directly held. (I) Indicates that some (or all) of these shares are held indirectly.